Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Abuse Liability of IQOS Heated Tobacco Products Among Adults Who Smoke

27 de agosto de 2026 actualizado por: Alayna Tackett, Ohio State University Comprehensive Cancer Center

Studying User Sensory Experiences and Smoking Behavior of IQOS Heated Tobacco Products to Improve Harm Reduction Among Adult Cigarette Smokers

This clinical trial aims to evaluate user sensory experiences and smoking behavior when using IQOS heated tobacco products (HTPs) among adults who smoke cigarettes.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVES:

I. Assess the abuse liability (appeal and sensory effects) of IQOS. II. Examine the puffing topography of IQOS.

SECONDARY OBJECTIVES:

I. Evaluate the impact of flavor on the sensory effects, appeal, and puffing topography of IQOS.

II. Evaluate the effect of perceived harm on IQOS use behavior.

EXPLORATORY OBJECTIVE:

I. Examine acute changes to pulmonary health associated with IQOS use.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants use IQOS HeatSticks (flavor matched to their usual cigarette) as much as desired (ad lib) over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants smoke their usual brand cigarette (UBC) ad lib over 60 minutes during laboratory visit 2.

ARM II: Participants smoke their UBC ad lib over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 2.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: The Ohio State University Comprehensive Cancer Center
  • Número de teléfono: 800-293-5066
  • Correo electrónico: OSUCCCClinicaltrials@osumc.edu

Ubicaciones de estudio

  • Estados Unidos
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • Ohio State University Comprehensive Cancer Center
        • Investigador principal:
          • Alayna P. Tackett, PhD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Adults 21-65 years
  • Adults who smoke (defined as ≥ 5 days weekly use of either menthol or non-menthol cigarettes over the past 3 months)
  • Willing to provide informed consent and abstain from using nicotine products 12 hours before each visit
  • Willing to bring UBC to each study visit
  • Read, write and speak English

Exclusion Criteria:

  • Current use of other non-combustible nicotine products (e.g., electronic [e]-cigarettes, HTPs; [defined as ≥ 5 days weekly use in the past 30 days])
  • Planning to quit nicotine use and/or use of any smoking cessation medication in the past 30 days
  • Current diagnosis of any lung diseases (e.g., asthma, cystic fibrosis, or chronic obstructive pulmonary disease)
  • Self-reported unstable or significant psychiatric conditions (past/stable conditions will be allowed)
  • History of cardiac event or distress within the past 3 months
  • Deaf, hard of hearing, or have a severe motor disability
  • Are currently pregnant, planning to become pregnant, or breastfeeding (urine pregnancy test will be completed at each visit throughout the study)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Arm I (IQOS HeatSticks, Usual Brand Cigarette [UBC])
Participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants smoke their UBC ad lib over 60 minutes during laboratory visit 2.
Conductual: Smoking Behavioral Research (IQOS)
Use IQOS HeatSticks (flavor matched to the participant's usual cigarette)
Conductual: Smoking Behavioral Research (UBC)
Smoke UBC
Otro: Arm II (UBC, IQOS HeatSticks)
Participants smoke their UBC ad lib over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 2.
Conductual: Smoking Behavioral Research (IQOS)
Use IQOS HeatSticks (flavor matched to the participant's usual cigarette)
Conductual: Smoking Behavioral Research (UBC)
Smoke UBC

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Product Appeal
Periodo de tiempo: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
Participants will complete the Appeal and Sensory Quality questionnaire. This questionnaire will ask participants to rate each study product for appeal characteristics such as liking, willingness to use again, flavor intensity, pleasantness of taste, etc. on a scale of 0 (not at all) - 100 (extremely). Higher scores indicate greater liking, willingness to use again, flavor intensity, etc.
Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
Product Sensory Attributes
Periodo de tiempo: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
Participants will rate sensory attributes using the Appeal and Sensory Quality questionnaire. This questionnaire will ask participants to rate each study product for sensory attributes such as harshness, coolness, sweetness, etc. on a scale of 0 (not at all) - 100 (extremely). Higher scores indicate greater harshness, coolness, sweetness, etc.
Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
Economic demand breakpoint
Periodo de tiempo: Minute 60 of product use session
The price point at which a participant is no longer willing to pay for a stick of the study product will be determined by using a cigarette purchase task questionnaire.
Minute 60 of product use session
Satisfaction and psychological reward
Periodo de tiempo: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
Satisfaction and psychological reward of study product use will be measured by the Modified Cigarette Evaluation Questionnaire (mCEQ). The mCEQ asks questions relating to satisfaction of using the study product on a scale from 0 (Not at all) - 6 (Extremely).
Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session
Abuse Liability Via Puff Topography - Total Smoking Time
Periodo de tiempo: Minute 60 of product use session
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.
Minute 60 of product use session
Abuse Liability Via Puff Topography - Average Puff Duration
Periodo de tiempo: Minute 60 of product use session
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.
Minute 60 of product use session
Abuse Liability Via Puff Topography - Average Flow Rate
Periodo de tiempo: Minute 60 of product use session
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.
Minute 60 of product use session
Abuse Liability Via Puff Topography - Average Inter-Puff Interval
Periodo de tiempo: Minute 60 of product use session
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.
Minute 60 of product use session
Abuse Liability Via Puff Topography - Average Puff Volume
Periodo de tiempo: Minute 60 of product use session
Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.
Minute 60 of product use session
Craving/withdrawal
Periodo de tiempo: Minute 0 before product use session, Minute 5 of product use session, Minute 35 of product use session, minute 60 of product use session
Nicotine withdrawal and craving symptoms will be measured using the Minnesota Nicotine Withdrawal Scale (MNWS)
Minute 0 before product use session, Minute 5 of product use session, Minute 35 of product use session, minute 60 of product use session

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Spirometry FEV1
Periodo de tiempo: Minute 0 before start of product use session and minute 60 of product use session
Spirometry will be used to measure forced expiratory volume (FEV1)
Minute 0 before start of product use session and minute 60 of product use session
Spirometry FVC
Periodo de tiempo: Minute 0 before start of product use session, Minute 60 of product use session
Spirometry will be used to measure forced vital capacity (FVC)
Minute 0 before start of product use session, Minute 60 of product use session
Spirometry FEV1/FVC
Periodo de tiempo: Minute 0 before start of product use session, Minute 60 of product use session
Spirometry will be used to measure FEV1/FVC
Minute 0 before start of product use session, Minute 60 of product use session
Used filter count
Periodo de tiempo: Minute 60 of product use session
Will assess the number of study product consumed
Minute 60 of product use session
Harm Perception
Periodo de tiempo: Minute 60 of product use session
A harm perception questionnaire will be used to assess the relative and absolute perceived harm of IQOS products.
Minute 60 of product use session

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Ohio State University Comprehensive Cancer Center

Colaboradores

National Cancer Institute (NCI)

Investigadores

  • Investigador principal: Alayna P Tackett, PhD, Ohio State University Comprehensive Cancer Center

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de agosto de 2026

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

26 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de julio de 2026

Publicado por primera vez (Actual)

7 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

31 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • OSU-26080
  • U54CA287392 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2026-04495 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • STUDY20260624 (Otro identificador: Ohio State University Comprehensive Cancer Center)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir